UnknownPhase 2NCT01380275

Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.

Studying Bone sarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Center, Korea
Principal Investigator
Byung-Kiu Park, M.D.,Ph.D.
Pediatric Oncology Branch, National Cancer Center, Korea
Intervention
Docetaxel (Taxotere)(drug)
Enrollment
35 enrolled
Eligibility
5-49 years · All sexes
Timeline
2008 – 2014

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01380275 on ClinicalTrials.gov

Other trials for Bone sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Bone sarcoma →

← Back to all trials